Drug Profile
Research programme: peptide-based therapeutics - Longevity Biotech
Alternative Names: 5A apoA-I mimetic peptide; LBT 3627; LBT-6030Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Longevity Biotech
- Developer Longevity Biotech; University of Nebraska Medical Center
- Class Neuroprotectants; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists; Vasoactive intestinal polypeptide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Neurological disorders; Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Asthma in USA (Inhalation, Inhalant)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Neurological-disorders in USA (PO)